Sa1637 High Efficacy of Ledipasvir/Sofosbuvir Plus Ribavirin Among Patients With Decompensated Cirrhosis Who Underwent Liver Transplant During Participation in the SOLAR-1 and SOLAR-2 Studies

After the Direct-acting Antivirals Are Gone, There Is Still Work to Be Done in the Liver

“…A separate analysis from the SOLAR-1 and SOLAR-2 studies of 17 patients of whom the majority had MELD scores of >15 and who underwent OLT after therapy with ledipasvir, sofosbuvir, and ribavirin demonstrated that an 11-week course of treatment was associated with no posttransplant virologic relapses. 12 Finally, given the high SVR rates that can be achieved posttransplantation with a variety of DAAs, treating HCV infection after OLT is an attractive option that could eliminate the complication of timing of OLT. In many parts of the world, including areas where OLT is available, access to organs is limited, and thus DAA therapy to achieve SVR is undertaken before OLT.…”